	US 11,981,754 B2
	Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
Aleksander S. Popel, Lutherville-Timonium, MD (US); Niranjan B. Pandey, White Marsh, MD (US); Esak Lee, Windsor Mill, MD (US); Jordan J. Green, Nottingham, MD (US); and Ron B. Shmueli, Baltimore, MD (US)
Assigned to THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD (US)
Filed by THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD (US)
Filed on Aug. 10, 2020, as Appl. No. 16/989,416.
Application 16/989,416 is a continuation of application No. 15/712,890, filed on Sep. 22, 2017, granted, now 10,774,112.
Application 15/712,890 is a continuation of application No. 14/896,521, granted, now 9,802,984, issued on Oct. 31, 2017, previously published as PCT/US2014/041526, filed on Jun. 9, 2014.
Claims priority of provisional application 61/832,290, filed on Jun. 7, 2013.
Prior Publication US 2020/0361993 A1, Nov. 19, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 7/08 (2006.01); A61K 38/10 (2006.01); A61K 45/06 (2006.01); B82Y 5/00 (2011.01); C12N 15/88 (2006.01)

CPC C07K 7/08 (2013.01) [A61K 38/10 (2013.01); A61K 45/06 (2013.01); B82Y 5/00 (2013.01); C12N 15/88 (2013.01); C12N 2510/00 (2013.01)]

29 Claims

1. A method for treating a condition associated with angiogenesis, lymphangiogenesis, vascular permeability, or tumorigenesis, comprising administering an effective amount of a peptide comprising the amino acid sequence of LRRFSTXPXXXXDINDVXNF (SEQ ID NO: 2), wherein X is any amino acid and the amino acid sequence is at least 85% identical to LRRFSTAPFAFIDINDVINF (SEQ ID NO: 1) and wherein X at position 7 is selected from M, A, and G; X at position 9 is selected from F, A, Y, and G, X at position 10 is selected from M, A, G, dA, and Nle, X at position 11 is selected from F, A, Y, G, and 4-C1Phe, and X at position 12 and position 18 are selected from Abu, G, S, A, V, T, I, L, and AllyGly.